Revere Partners has launched the first independent venture capital fund focused exclusively on oral health, identifying opportunities for investors and providing capital for cutting-edge innovations in the oral and systemic health sectors.
The fund has been operational for over two years and works with oral tech companies, startups, investors, and DSOs, fostering strategic partnerships that improve care delivery and patient and provider experiences, driving maximum returns for investors.
With annual spending on dental care in the US projected to surpass $230 billion by 2023, the dental industry – specifically early-stage dental technology startups – is positioned to experience strong growth in coming years. As an AngelList RollingFund, Revere Partners offers a unique, flexible structure with continuously open fundraising, operating as a quarterly subscription service and providing adaptable payment terms to accommodate all accredited investors. Revere Partners brings best-in-class oral health deal sourcing, diligence, and post-investment support to the oral and systemic health industry.
In launching Revere Partners, co-founders Dr Jeremy Krell and David Arena – a leadership duo with more than three decades of combined investor, entrepreneur, and dental industry experience, identified an untapped industry positioned for investment and improved care delivery. Krell’s background includes multiple startup exits followed by dental professional development at quip, the subscription electronic toothbrush company, and also strategic provider innovation and development at Oscar Health, which underwent an IPO in March 2021. Arena’s burgeoning career as an investor, technologist and financial professional includes nearly a decade of advising institutional clients on investment strategy and developing systematic trading strategies at Bridgewater Associates, while also spending nearly ten years as a Chief Financial Officer across startups.
Revere Partners utilises a rigorous research process that enables the fund to deliver unique insights to investors. The firm recently compiled data from over 700 transactions, comprising the largest database of its kind, and found a 33-35% internal rate of return (IRR) and 5.2x returns in 4.8 years on average across oral health-startups broadly.
